A2 Biotherapeutics
PrivateLast Round
Grant
May 6, 2025
Total Funding Raised
$270.8M
Company Overview
A2 Biotherapeutics operates in Healthcare & Life Sciences and is based in Agoura Hills, California. Its latest recorded funding round was a Grant round in May 2025.
A2 Biotherapeutics is a biotechnology company that develops logic-gated cell therapies for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
A2 Biotherapeutics Comparables
Compare A2 Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ArsenalBio | 89% | |
| Eureka Therapeutics | 82% | |
| Link Cell Therapies | 82% |
For institutional investors. Book with your work email.
A2 Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 6, 2025 | ||||
| Series C | Jan 9, 2025 | ||||
| Series B Extension | Dec 19, 2022 | ||||
| Series B | Oct 6, 2020 | ||||
| Series A Extension | Nov 5, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
A2 Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series A Extension, Series C |
| Perceptive Advisors | Series C |
| Vida Ventures | Series B, Series C, Series A Extension |
| Aisling Capital | Series C |
| Casdin Capital | Series B |
| Nextech Invest | Series B, Series A Extension |
| UC Investments | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Three abstracts accepted for presentation at the 2026 ASCO Annual Meeting.
- Oct 3, 2025
Four abstracts accepted for the Society for Immunotherapy of Cancer meeting.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
A2 Biotherapeutics, Inc. plans to announce early safety and efficacy findings from the DENALI-1 Study of A2B395 at the 2026 Cell Coast Conference.
For institutional investors. Book with your work email.
A2 Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about A2 Biotherapeutics's valuation, stock price, and market status.
Is A2 Biotherapeutics a public or private company?
A2 Biotherapeutics is a private company.
What is the current stock price of A2 Biotherapeutics?
A2 Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks A2 Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is A2 Biotherapeutics worth (valuation)?
Valuation information for A2 Biotherapeutics is not publicly available.
Can I buy A2 Biotherapeutics stock?
A2 Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was A2 Biotherapeutics's last funding round?
A2 Biotherapeutics's most recent funding round was Grant on May 6, 2025.
Who are the main investors in A2 Biotherapeutics?
Key investors in A2 Biotherapeutics include The Column Group, Vida Ventures, Casdin Capital, Nextech Invest, Samsara BioCapital.
Will A2 Biotherapeutics IPO soon?
No public IPO plans have been announced for A2 Biotherapeutics.
How can I track A2 Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in A2 Biotherapeutics's shares on secondary markets.